Recorded Chinese product: 厄贝沙坦分散片厄贝沙坦分散片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 济南利民制药有限责任公司Chinese legal name: 济南利民制药有限责任公司
主要成分Active Ingredients
- 厄贝沙坦Ebei Shatan
- 二氮杂螺-[]壬--烯--酮
药物知识说明
厄贝沙坦是一种在国家药监局注册认定的药品。该药品含有厄贝沙坦-9fe6c189等成分。
该药品关联的活性成分包括：厄贝沙坦Ebei Shatan。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：济南利民制药有限责任公司Chinese legal name: 济南利民制药有限责任公司。
您可以探索含有相同成分的其他药品：厄贝沙坦-9fe6c189成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 厄贝沙坦分散片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 厄贝沙坦Ebei Shatan.
Manufacturers recorded for this product: 济南利民制药有限责任公司Chinese legal name: 济南利民制药有限责任公司.
Explore other medicines containing the same ingredient: 厄贝沙坦 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 厄贝沙坦分散片Recorded Chinese product: 厄贝沙坦分散片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 0.15g*12片0.15 g × 12 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 济南利民制药有限责任公司Chinese legal name: 济南利民制药有限责任公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20100170
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20100170
Manufacturer
Chinese legal name: 济南利民制药有限责任公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
0.15 g × 12 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20100170
生产企业
济南利民制药有限责任公司(国产)
适应症
1.治疗原发性高血压。 2.合并高血压的2型糖尿病肾病的治疗。
用法用量
口服：推荐起始剂量为0.15g，一日1次。根据病情可增至0.3g，一日1次。可单独使用，也可与其它抗高血压药物合用。对重度高血压及药物增量后血压下降仍不满意时，可加用小剂量的利尿药(如噻嗪类)或其它降压药物。
不良反应
常见不良反应为：头痛、眩晕、心悸等，偶有咳嗽，一般程度都是轻微的，呈一过性，多数患者继续服药都能耐受。罕有荨麻疹及血管神经性水肿发生。文献报道本品不良反应发生率大于1%的有：消化不良、胃灼热感、腹泻、骨骼肌疼痛、疲劳和上呼吸道感染，但与空白对照组比没有显著性差异。大于1%但低于对照组发生率的有腹痛、焦虑、神经质、胸痛、咽炎、恶心呕吐、皮疹、心动过速等。低血压和直立性低血压发生率约为0.4%。
禁忌
对本品过敏者禁用。
注意事项
1.开始治疗前应纠正血容量不足和(或)钠的缺失。
2.肾功能不全的患者可能需要减少本品的剂量。并且要注意血尿素氮、血清肌酐和血钾的变化。作为肾素-血管紧张素-醛固酮抑制的结果，个别敏感的患者可能产生肾功能变化。
3.肝功能不全、老年患者使用本品时不需调节剂量。
4.厄贝沙坦不能通过血液透析被排出体外。
贮藏
密封保存。
规格
0.15g*12片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.